Latest Insider Transactions at Arrowhead Pharmaceuticals, Inc. (ARWR)
This section provides a real-time view of insider transactions for Arrowhead Pharmaceuticals, Inc. (ARWR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARROWHEAD PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARROWHEAD PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 02
2024
|
Tracie Oliver Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
9,394
-6.88%
|
$234,850
$25.28 P/Share
|
|
May 02
2024
|
Victoria Vakiener Director |
SELL
Open market or private sale
|
Direct |
1,799
-5.62%
|
$41,377
$23.31 P/Share
|
|
Apr 01
2024
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
6,000
-2.85%
|
$168,000
$28.03 P/Share
|
|
Mar 20
2024
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Direct |
1,000
+2.88%
|
$27,000
$27.5 P/Share
|
|
Mar 19
2024
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Direct |
1,000
+2.97%
|
$28,000
$28.0 P/Share
|
|
Mar 18
2024
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Direct |
1,000
+3.06%
|
$27,000
$27.49 P/Share
|
|
Mar 06
2024
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
40,000
-9.08%
|
$1,400,000
$35.19 P/Share
|
|
Jan 31
2024
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,499
-0.76%
|
$1,839,968
$32.43 P/Share
|
|
Jan 31
2024
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,499
+1.5%
|
$804,986
$14.54 P/Share
|
|
Jan 12
2024
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
7,940
-1.83%
|
$285,840
$36.92 P/Share
|
|
Jan 11
2024
|
Victoria Vakiener Director |
SELL
Open market or private sale
|
Direct |
4,720
-6.59%
|
$179,360
$38.36 P/Share
|
|
Jan 11
2024
|
Mauro Ferrari Director |
SELL
Open market or private sale
|
Direct |
3,147
-2.49%
|
$119,586
$38.22 P/Share
|
|
Jan 11
2024
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
3,934
-3.86%
|
$149,492
$38.2 P/Share
|
|
Jan 11
2024
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
2,911
-1.1%
|
$110,618
$38.15 P/Share
|
|
Jan 05
2024
|
Martin Javier San Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,303
-1.35%
|
$282,302
$34.93 P/Share
|
|
Jan 05
2024
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
16,104
-1.19%
|
$547,536
$34.89 P/Share
|
|
Jan 05
2024
|
Tracie Oliver Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
74
-0.05%
|
$2,442
$33.89 P/Share
|
|
Jan 05
2024
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
32,143
-3.35%
|
$1,092,862
$34.9 P/Share
|
|
Jan 05
2024
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
22,841
-1.58%
|
$776,594
$34.88 P/Share
|
|
Jan 04
2024
|
Martin Javier San Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+26.61%
|
-
|
|
Jan 04
2024
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+14.11%
|
-
|
|
Jan 04
2024
|
Tracie Oliver Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+35.45%
|
-
|
|
Jan 04
2024
|
James C Hamilton Chief Discovery/Trans Medicine |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+23.01%
|
-
|
|
Jan 04
2024
|
Patrick O'Brien COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+14.85%
|
-
|
|
Jan 04
2024
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
1,600
-0.4%
|
$51,200
$32.63 P/Share
|
|
Jan 03
2024
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
6,300
-1.16%
|
$201,600
$32.54 P/Share
|
|
Jan 03
2024
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
8,749
-0.53%
|
$279,968
$32.6 P/Share
|
|
Jan 02
2024
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,952
-0.13%
|
$298,560
$31.0 P/Share
|
|
Dec 20
2023
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,000
-0.32%
|
$336,000
$28.54 P/Share
|
|
Dec 15
2023
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+18.55%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+11.55%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
Douglas B Given Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+10.15%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
Victoria Vakiener Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+28.98%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
Adeoye Y Olukotun Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+39.61%
|
$374,675
$25.41 P/Share
|
|
Dec 15
2023
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,987
+22.44%
|
$374,675
$25.41 P/Share
|
|
Nov 20
2023
|
Martin Javier San Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,700
-6.68%
|
$551,600
$28.87 P/Share
|
|
Oct 25
2023
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,338
-0.65%
|
$584,112
$24.21 P/Share
|
|
Sep 28
2023
|
Victoria Vakiener Director |
SELL
Open market or private sale
|
Direct |
1,550
-6.66%
|
$40,300
$26.33 P/Share
|
|
Sep 18
2023
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,755
-0.76%
|
$1,617,140
$28.14 P/Share
|
|
Sep 18
2023
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,755
+1.49%
|
$231,020
$4.75 P/Share
|
|
Jul 03
2023
|
Tracie Oliver Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,925
-12.66%
|
$312,375
$35.31 P/Share
|
|
Jun 30
2023
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
3,000
-1.57%
|
$105,000
$35.53 P/Share
|
|
Jun 27
2023
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-3.78%
|
$540,000
$36.2 P/Share
|
|
May 05
2023
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
6,500
-5.24%
|
$260,000
$40.9 P/Share
|
|
May 04
2023
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-0.66%
|
$1,950,000
$39.5 P/Share
|
|
May 04
2023
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+1.29%
|
$100,000
$2.01 P/Share
|
|
May 03
2023
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
54,928
-1.44%
|
$2,142,192
$39.14 P/Share
|
|
May 03
2023
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
54,928
+1.42%
|
$109,856
$2.01 P/Share
|
|
Mar 03
2023
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
11,350
-59.06%
|
$363,200
$32.65 P/Share
|
|
Feb 27
2023
|
Douglas B Given Director |
SELL
Open market or private sale
|
Indirect |
875
-6.31%
|
$28,000
$32.62 P/Share
|